Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297652 | 0.94 | SPHK1 (0.36) | SPHK1LGALS8THRBLMNALGALS3 | |
| SCHEMBL13467759 | 0.94 | SPHK1 (0.36) | SPHK1LGALS8THRBLMNALGALS3 | |
| SCHEMBL19276934 | 0.86 | SPHK1 (0.34) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL21233490 | 0.86 | SPHK1 (0.34) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL19721647 | 0.86 | SPHK1 (0.34) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL23603158 | 0.86 | LGALS3 (0.37) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL23603330 | 0.86 | LGALS3 (0.37) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL22423210 | 0.86 | LGALS3 (0.37) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL18104016 | 0.86 | SPHK1 (0.34) | SPHK1LGALS8LGALS3GAAMGAM | |
| SCHEMBL8719944 | 0.86 | LGALS3 (0.37) | SPHK1LGALS8LGALS3GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235076-A1 | HUMANIZED ANTIBODIES AGAINST LEWIS Y | PENTIXAPHARM AG (DE) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235076-A1 | HUMANIZED ANTIBODIES AGAINST LEWIS Y | FCGR2A, FCGR3B, CD47 | SPHK1 3311/4885LGALS8 62/4885THRB 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.